Bacteriocins and Its Use for Multidrug-Resistant Bacteria Control

Preciado, Guadalupe Mondragón; Michel, M.M.; Villarreal-Morales, S.L.; Flores‐Gallegos, Adriana C.; Aguirre-Joya, Jorge A.; Morlett-Chávez, Jesús A.; Aguilar, Cristóbal N.; Rodríguez‐Herrera, Raúl

doi:10.1016/b978-0-12-803642-6.00016-2

Cited by 26 publications

(18 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several in vitro and in vivo studies have evaluated their therapeutic use in small animals, livestock, and poultry ( Table 2 ). This evidence demonstrates that bacteriocins can be applied as a substitute for antibiotics and represent an alternative as new antimicrobials that prevent bacterial resistance [ 22 , 60 ].…”

Section: The Antimicrobial Properties Of Bacteriocins In Veterinary Medicinementioning

confidence: 99%

Bacteriocins from Lactic Acid Bacteria. A Powerful Alternative as Antimicrobials, Probiotics, and Immunomodulators in Veterinary Medicine

Hernández-González

Martínez-Tapia

Lazcano-Hernández

et al. 2021

Animals

146

View full text Add to dashboard Cite

In the search for an alternative treatment to reduce antimicrobial resistance, bacteriocins shine a light on reducing this problem in public and animal health. Bacteriocins are peptides synthesized by bacteria that can inhibit the growth of other bacteria and fungi, parasites, and viruses. Lactic acid bacteria (LAB) are a group of bacteria that produce bacteriocins; their mechanism of action can replace antibiotics and prevent bacterial resistance. In veterinary medicine, LAB and bacteriocins have been used as antimicrobials and probiotics. However, another critical role of bacteriocins is their immunomodulatory effect. This review shows the advances in applying bacteriocins in animal production and veterinary medicine, highlighting their biological roles.

show abstract

Section: The Antimicrobial Properties Of Bacteriocins In Veterinary Medicinementioning

confidence: 99%

Bacteriocins from Lactic Acid Bacteria. A Powerful Alternative as Antimicrobials, Probiotics, and Immunomodulators in Veterinary Medicine

Hernández-González

Martínez-Tapia

Lazcano-Hernández

et al. 2021

Animals

146

View full text Add to dashboard Cite

show abstract

“…Several known and unknown postbiotic compounds, such as bacteriocins, enzymes, small molecules, and organic acids, exhibit bacteriostatic or bactericidal properties against both Gram-positive and Gram-negative microorganisms [232]. For instance, nisin A, produced by Lactococcus lactis, is a pore-forming bacteriocin that binds the peptidoglycan precursor lipid II preventing its binding with penicillin and leading to rapid cell death [233].…”

Section: Antimicrobial Activitymentioning

confidence: 99%

Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?

et al. 2020

View full text Add to dashboard Cite

Mismanagement of bacterial infection therapies has undermined the reliability and efficacy of antibiotic treatments, producing a profound crisis of the antibiotic drug market. It is by now clear that tackling deadly infections demands novel strategies not only based on the mere toxicity of anti-infective compounds. Host-directed therapies have been the first example as novel treatments with alternate success. Nevertheless, recent advances in the human microbiome research have provided evidence that compounds produced by the microbial metabolism, namely postbiotics, can have significant impact on human health. Such compounds target the host-microbe-pathogen interface rescuing biotic and immune unbalances as well as inflammation, thus providing novel therapeutic opportunities. This work discusses critically, through literature review and personal contributions, these novel nonantibiotic treatment strategies for infectious disease management and resistance prevention, which could represent a paradigm change rocking the foundation of current antibiotic therapy tenets.

show abstract

“…coli , and Planomonospora sp. have demonstrated to be more effective than other approved antibiotics for the treatment of MDR pathogens [ 59 ]. Although our study did not evaluate pure compounds, the use of semipurified crude extract or the producer strain as a probiotic agent could be applied in food [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

Growth inhibition of pathogenic microorganisms by Pseudomonas protegens EMM-1 and partial characterization of inhibitory substances

et al. 2020

View full text Add to dashboard Cite

The bacterial strain, EMM-1, was isolated from the rhizosphere of red maize ("Rojo Criollo") and identified as Pseudomonas protegens EMM-1 based on phylogenetic analysis of 16S rDNA, rpoB, rpoD, and gyrB gene sequences. We uncovered genes involved in the production of antimicrobial compounds like 2,4-diacetylphloroglucinol (2,4-DAPG), pyoluteorin, and lectin-like bacteriocins. These antimicrobial compounds are also produced by other fluorescent pseudomonads alike P. protegens. Double-layer agar assay showed that P. protegens EMM-1 inhibited the growth of several multidrug-resistant (MDR) bacteria, especially clinical isolates of the genera Klebsiella and β-hemolytic Streptococcus. This strain also displayed inhibitory effects against diverse fungi, such as Aspergillus, Botrytis, and Fusarium. Besides, a crude extract of inhibitory substances secreted into agar was obtained after the cold-leaching process, and physicochemical characterization was performed. The partially purified inhibitory substances produced by P. protegens EMM-1 inhibited the growth of Streptococcus sp. and Microbacterium sp., but no inhibitory effect was noted for other bacterial or fungal strains. The molecular weight determined after ultrafiltration was between 3 and 10 kDa. The inhibitory activity was thermally stable up to 60˚C (but completely lost at 100˚C), and the inhibitory activity remained active in a wide pH range (from 3 to 9). After treatment with a protease from Bacillus licheniformis, the inhibitory activity was decreased by 90%, suggesting the presence of proteic natural compounds. All these findings suggested that P. protegens EMM-1 is a potential source of antimicrobials to be used against pathogens for humans and plants.

show abstract

Bacteriocins and Its Use for Multidrug-Resistant Bacteria Control

Cited by 26 publications

References 76 publications

Bacteriocins from Lactic Acid Bacteria. A Powerful Alternative as Antimicrobials, Probiotics, and Immunomodulators in Veterinary Medicine

Bacteriocins from Lactic Acid Bacteria. A Powerful Alternative as Antimicrobials, Probiotics, and Immunomodulators in Veterinary Medicine

Postbiotic-Enabled Targeting of the Host-Microbiota-Pathogen Interface: Hints of Antibiotic Decline?

Growth inhibition of pathogenic microorganisms by Pseudomonas protegens EMM-1 and partial characterization of inhibitory substances

Contact Info

Product

Resources

About